Symptomatic Recurrence and Survival Outcomes After Curative Treatment of Gastric Cancer: Does Intensive Follow-up Evaluation Improve Survival?

Diniz, Thiago Pereira; Costa, Wilson Luiz da; Gomes, Camila Couto; Jesus, Victor Hugo Fonseca de; Felismino, Tiago; Torres, Sílvio Melo; Ribeiro, Héber S. C.; Diniz, Alessandro Landskron; Godoy, A.; Farias, Igor Correia de; Dias‐Neto, Emmanuel; Curado, María Paula; Coimbra, Felipe José Fernández

doi:10.1245/s10434-021-10724-5

Cited by 9 publications

(17 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ten studies ( 22 – 27 , 29 – 32 ) involving 1836 patients (795 in the AR group and 1041 in the SR group) reported the OS outcome. Briefly, five studies ( 22 , 23 , 26 , 30 , 32 ) showed patients in the AR group had a superior OS than patients in the SR group, but another five studies ( 24 , 25 , 27 , 29 , 31 ) showed no differences between the two groups. After adding these results, the pooled HR was 0.67 (95%CI: 0.57-0.79; P<0.001), which indicated that the detection of AR could improve the OS in GC patients undergoing curative resection ( Figure 2 and Table 2 ), although there was a moderate heterogeneity (I 2 = 53%; P=0.02).…”

Section: Resultsmentioning

confidence: 99%

“…Consistently, our clinicopathological analysis also confirmed that the SR group had more advanced T staging. Meanwhile, Diniz et al (24) demonstrated that patients with peritoneal recurrence had a worse OS when compared with these with other recurrence patterns, which may partially explain why patients in the SR group had an inferior long-term survival. However, in cases with peritoneal recurrence, Fujiya et al group still had an obviously improved OS than these in the SR group (median OS: 35.9 vs. 24.0 months; P=0.039).…”

Section: Discussionmentioning

confidence: 99%

“…The search strategy yielded 2296 potential studies. After title, abstract assessment and full text assessment, 11 retrospective cohort studies (22)(23)(24)(25)(26)(27)(28)(29)(30)(31)(32) were finally included in the present study. The characteristics of the included studies were shown in Table 1.…”

Section: Study Characteristicsmentioning

confidence: 99%

“…Ten studies (22)(23)(24)(25)(26)(27)(29)(30)(31)(32) involving 1836 patients (795 in the AR group and 1041 in the SR group) reported the OS outcome. Briefly, five studies (22,23,26,30,32) showed patients in the AR group had a superior OS than patients in the SR group, but another five studies (24,25,27,29,31) showed no differences between the two groups.…”

Section: Overall Survivalmentioning

confidence: 99%

See 3 more Smart Citations

Detection of asymptomatic recurrence following curative surgery improves survival in patients with gastric cancer: A systematic review and meta-analysis

et al. 2022

View full text Add to dashboard Cite

BackgroundTo date, there is no evidence that intensive follow-up provides survival benefit in gastric cancer patients undergoing curative gastrectomy. The aim of this study is to investigate the efficacy of detection of asymptomatic recurrence using intensive surveillance strategy in long-term survival after curative gastric cancer surgery.MethodsA systematic review of electronic databases including PubMed, Embase, Web of Science, the Cochrane Library and China National Knowledge Infrastructure, Clinical Trials Registry and Google Scholar was performed up to April 2022. The primary outcomes were survival outcomes: overall survival, recurrence-free survival and post-recurrence survival. The secondary endpoints were clinicopathological features, recurrence patterns and treatment after recurrence. The registration number of this protocol is PROSPERO CRD42022327370.ResultsA total of 11 studies including 1898 participants were included. In the pooled analysis, the detection of asymptomatic recurrence was significantly associated with an improved overall survival compared to patients showing symptoms of recurrence (HR=0.67; 95%CI: 0.57-0.79; P<0.001), which was primarily driven by the prolongation of post-recurrence survival (HR=0.51; 95%CI: 0.42-0.61; P<0.001), since there was no significant difference observed in recurrence-free survival (HR=1.12; 95%CI: 0.81-1.55; P=0.48) between the two groups. Meanwhile, male sex and advanced T stage were more frequently observed in the symptomatic recurrence group. Furthermore, patients in the symptomatic recurrence group had a higher proportion of peritoneal relapse but lower proportion of distant lymph node metastasis. Additionally, patients in the symptomatic recurrence group were less likely to receive surgery treatment and post-recurrence chemotherapy.ConclusionThe detection of asymptomatic recurrence using intensive follow-up was associated with an appreciable improvement in overall survival. However, more robust data from high-quality studies are still required to verify this issue.Systematic review registrationhttps://www.crd.york.ac.uk/prospero/display_record.php?RecordID=327370, identifier CRD42022327370.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Study Characteristicsmentioning

confidence: 99%

Section: Overall Survivalmentioning

confidence: 99%

See 2 more Smart Citations

Detection of asymptomatic recurrence following curative surgery improves survival in patients with gastric cancer: A systematic review and meta-analysis

et al. 2022

View full text Add to dashboard Cite

show abstract

“…In recent decades, several reports have shown that lncRNAs (Yin et al, 2018;Diniz et al, 2021;Homayoonfal et al, 2021) play important roles in tumor progression and could be biomarkers for clinical treatments. Increasing studies have demonstrated that DUXAP10 is involved in the tumorigenesis and development of tumors through the modulation of diverse cellular processes, comprising cell colony formation, cell cycle progression, cell proliferation, apoptosis, metastasis, and even CSC-like properties.…”

Section: Duxap10 As a Treatment Targetmentioning

confidence: 99%

The LncRNA DUXAP10 Could Function as a Promising Oncogene in Human Cancer

Zhao

Dong

et al. 2022

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Cancer is one of the most prevalent and deadliest diseases globally, with an increasing morbidity of approximately 14 million new cancer cases per year. Identifying novel diagnostic and prognostic biomarkers for cancers is important for developing cancer therapeutic strategies and lowering mortality rates. Long noncoding RNAs (lncRNAs) represent a group of noncoding RNAs of more than 200 nucleotides that have been shown to participate in the development of human cancers. The novel lncRNA DUXAP10 was newly reported to be abnormally overexpressed in several cancers and positively correlated with poor clinical characteristics of cancer patients. Multiple studies have found that DUXAP10 widely regulates vital biological functions related to the development and progression of cancers, including cell proliferation, apoptosis, invasion, migration, and stemness, through different molecular mechanisms. The aim of this review was to recapitulate current findings regarding the roles of DUXAP10 in cancers and evaluate the potential of DUXAP10 as a novel biomarker for cancer diagnosis, treatment, and prognostic assessment.

show abstract

Peritoneal metastases from gastric cancer in a nationwide cohort: Incidence, treatment and survival

Rijken,

Pape,

Simkens

et al. 2023

Intl Journal of Cancer

View full text Add to dashboard Cite

The aims of this study were to investigate incidence, risk factors and treatment of synchronous or metachronous peritoneal metastases (PM) from gastric cancer and to estimate survival of these patients using population‐based data. Patients diagnosed with gastric cancer in 2015 to 2016 were selected from the Netherlands Cancer Registry. The incidence of synchronous and metachronous PM were calculated. Multivariable regression analyses were performed to identify factors associated with the occurrence of PM. Treatment and survival were compared between patients with synchronous and metachronous PM. Of 2206 patients with gastric cancer, 741 (34%) were diagnosed with PM. Of these, 498 (23%) had synchronous PM. The cumulative incidence of metachronous PM in patients who underwent potentially curative treatment (n = 675) was 22.8% at 3 years. A factor associated with synchronous and metachronous PM was diffuse type histology. Patients diagnosed with synchronous PM more often received systemic treatment than patients with metachronous PM (35% vs 18%, respectively, P < .001). Median overall survival was comparable between synchronous and metachronous PM (3.2 vs 2.3 months, respectively, P = .731). Approximately one third of all patients with gastric cancer are diagnosed with PM, either at primary diagnosis or during 3‐year follow‐up after potentially curative treatment. Patients with metachronous PM less often received systemic treatment than those with synchronous PM but survival was comparable between both groups. Future trials are warranted to detect gastric cancer at an earlier stage and to examine strategies that lower the risk of peritoneal dissemination. Also, specific treatment options for patients with gastric PM should be further investigated.

show abstract

Symptomatic Recurrence and Survival Outcomes After Curative Treatment of Gastric Cancer: Does Intensive Follow-up Evaluation Improve Survival?

Cited by 9 publications

References 27 publications

Detection of asymptomatic recurrence following curative surgery improves survival in patients with gastric cancer: A systematic review and meta-analysis

Detection of asymptomatic recurrence following curative surgery improves survival in patients with gastric cancer: A systematic review and meta-analysis

The LncRNA DUXAP10 Could Function as a Promising Oncogene in Human Cancer

Peritoneal metastases from gastric cancer in a nationwide cohort: Incidence, treatment and survival

Contact Info

Product

Resources

About